{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:34:15Z","timestamp":1793266455687,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12381-0","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:11:42Z","timestamp":1753427502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models"],"prefix":"10.1038","volume":"15","author":[{"given":"Thomas","family":"Sorz-Nechay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Brusilovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"K\u00f6nigshofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt S.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Petrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Taru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bonitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Horstmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Zinober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Regnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Truebenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Kauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"6","key":"12381_CR1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","volume":"27","author":"F Triposkiadis","year":"2022","unstructured":"Triposkiadis, F., Xanthopoulos, A., Skoularigis, J. & Starling, R. C. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Fail. Rev. 27 (6), 1991\u20132003. https:\/\/doi.org\/10.1007\/s10741-022-10239-5 (2022).","journal-title":"Heart Fail. Rev."},{"key":"12381_CR2","doi-asserted-by":"publisher","unstructured":"Simonetto, D. A., Liu, M. & Kamath, P. S. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc.  94(4), 714\u2013726. https:\/\/doi.org\/10.1016\/j.mayocp.2018.12.020 (2019).","DOI":"10.1016\/j.mayocp.2018.12.020"},{"key":"12381_CR3","doi-asserted-by":"publisher","unstructured":"Kreisel, W. et al. Cyclic Gmp in liver cirrhosis\u2014role in pathophysiology of portal hypertension and therapeutic implications. Int. J. Mol. Sci. 22 (19). https:\/\/doi.org\/10.3390\/ijms221910372 (2021).","DOI":"10.3390\/ijms221910372"},{"issue":"7","key":"12381_CR4","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.117.303776","volume":"120","author":"JR Kraehling","year":"2017","unstructured":"Kraehling, J. R. & Sessa, W. C. Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease. Circ. Res. 120 (7), 1174\u20131182. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.303776 (2017).","journal-title":"Circ. Res."},{"key":"12381_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","volume":"81","author":"ER Derbyshire","year":"2012","unstructured":"Derbyshire, E. R. & Marletta, M. A. Structure and regulation of soluble guanylate cyclase. Annu. Rev. Biochem. 81, 533\u2013559. https:\/\/doi.org\/10.1146\/annurev-biochem-050410-100030 (2012).","journal-title":"Annu. Rev. Biochem."},{"issue":"7","key":"12381_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1515\/hsz-2018-0155","volume":"399","author":"P Sandner","year":"2018","unstructured":"Sandner, P. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol. Chem. 399 (7), 679\u2013690. https:\/\/doi.org\/10.1515\/hsz-2018-0155 (2018).","journal-title":"Biol. Chem."},{"issue":"33","key":"12381_CR7","doi-asserted-by":"publisher","first-page":"30737","DOI":"10.1074\/jbc.M102549200","volume":"276","author":"M Koglin","year":"2001","unstructured":"Koglin, M., Vehse, K., Budaeus, L., Scholz, H. & Behrends, S. Nitric oxide activates the \u03b22 subunit of soluble Guanylyl cyclase in the absence of a second subunit. J. Biol. Chem. 276 (33), 30737\u201330743. https:\/\/doi.org\/10.1074\/jbc.M102549200 (2001).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"12381_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","volume":"393","author":"A Friebe","year":"2020","unstructured":"Friebe, A., Sandner, P. & Schmidtko, A. cGMP: a unique 2nd messenger molecule \u2013 recent developments in cGMP research and development. Naunyn Schmiedebergs Arch. Pharmacol. 393 (2), 287\u2013302. https:\/\/doi.org\/10.1007\/s00210-019-01779-z (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"12381_CR9","doi-asserted-by":"publisher","unstructured":"Gambaryan, S. The role of no\/sgc\/cgmp\/pkg signaling pathway in regulation of platelet function. Cells 11 (22). https:\/\/doi.org\/10.3390\/cells11223704 (2022).","DOI":"10.3390\/cells11223704"},{"issue":"5","key":"12381_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","volume":"165","author":"T Keravis","year":"2012","unstructured":"Keravis, T. & Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br. J. Pharmacol. 165 (5), 1288\u20131305. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01729.x (2012).","journal-title":"Br. J. Pharmacol."},{"key":"12381_CR11","doi-asserted-by":"crossref","unstructured":"Theilig, F. et al. Cellular Distribution and Function of Soluble Guanylyl Cyclase in Rat Kidney and Liver. http:\/\/journals.lww.com\/jasn (2001).","DOI":"10.1681\/ASN.V12112209"},{"issue":"5","key":"12381_CR12","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/hep.31987\/suppinfo","volume":"74","author":"W Yang","year":"2021","unstructured":"Yang, W. et al. Single-Cell transcriptomic analysis reveals a hepatic stellate Cell-Activation roadmap and myofibroblast origin during liver fibrosis in mice. Liver Biol. Pathobiol. Hepatol. 74 (5), 2021. https:\/\/doi.org\/10.1002\/hep.31987\/suppinfo (2021).","journal-title":"Liver Biol. Pathobiol. Hepatol."},{"key":"12381_CR13","doi-asserted-by":"publisher","unstructured":"Schwabl, P. et al. The soluble guanylate cyclase stimulator Riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci. Rep. 8 (1). https:\/\/doi.org\/10.1038\/s41598-018-27656-y (2018).","DOI":"10.1038\/s41598-018-27656-y"},{"key":"12381_CR14","doi-asserted-by":"publisher","unstructured":"Flores-Costa, R. et al. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP\/ NF-\u03baB\/NLRP3 inflammasome circuit. https:\/\/doi.org\/10.1073\/pnas.2000466117\/-\/DCSupplemental","DOI":"10.1073\/pnas.2000466117\/-\/DCSupplemental"},{"issue":"38","key":"12381_CR15","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.3748\/wjg.v24.i38.4356","volume":"24","author":"D Schaffner","year":"2018","unstructured":"Schaffner, D. et al. Analysis of the nitric oxide-cyclic guanosine monophos pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J. Gastroenterol. 24 (38), 4356\u20134368. https:\/\/doi.org\/10.3748\/wjg.v24.i38.4356 (2018).","journal-title":"World J. Gastroenterol."},{"key":"12381_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1152\/ajpgi.00297.2005.-NO","volume":"290","author":"RE Perri","year":"2006","unstructured":"Perri, R. E. et al. Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. Am. J. Physiol. Gastrointest. Liver Physiol. 290, 535\u2013542. https:\/\/doi.org\/10.1152\/ajpgi.00297.2005.-NO (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"12381_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1440-1746.1997.tb00414.x","volume":"12","author":"P Kirstetter","year":"1997","unstructured":"Kirstetter, P. et al. Plasma concentrations of Cyclic 3\u2019,5\u2019-guanosine monophosphate in patients with cirrhosis: relationship with atrial natriuretic peptide and haemodynamics. J. Gastroenterol. Hepatol. (Australia). 12 (3), 233\u2013236. https:\/\/doi.org\/10.1111\/j.1440-1746.1997.tb00414.x (1997).","journal-title":"J. Gastroenterol. Hepatol. (Australia)"},{"key":"12381_CR18","unstructured":"Fern, C. M. et al. Enhanced Urinary Excretion of CGMP in liver cirrhosis relationship to hemodynamic changes, neurohormonal activation, and urinary sodium excretion."},{"issue":"3","key":"12381_CR19","doi-asserted-by":"publisher","first-page":"109301","DOI":"10.1016\/j.isci.2024.109301","volume":"27","author":"O Petrenko","year":"2024","unstructured":"Petrenko, O. et al. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension. iScience 27 (3), 109301. https:\/\/doi.org\/10.1016\/j.isci.2024.109301 (2024).","journal-title":"iScience"},{"issue":"22","key":"12381_CR20","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1073\/pnas.1821045116","volume":"166","author":"KC Hall","year":"2019","unstructured":"Hall, K. C. et al. SGC stimulator Praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc. Natl. Acad. Sci. USA. 166 (22), 11057\u201311062. https:\/\/doi.org\/10.1073\/pnas.1821045116 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"12381_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/bph.14137","volume":"175","author":"R Flores-Costa","year":"2018","unstructured":"Flores-Costa, R. et al. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br. J. Pharmacol. 175 (6), 953\u2013967. https:\/\/doi.org\/10.1111\/bph.14137 (2018).","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"12381_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/2050640620944140","volume":"8","author":"K Brusilovskaya","year":"2020","unstructured":"Brusilovskaya, K. et al. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 Inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United Eur. Gastroenterol. J. 8 (10), 1174\u20131185. https:\/\/doi.org\/10.1177\/2050640620944140 (2020).","journal-title":"United Eur. Gastroenterol. J."},{"key":"12381_CR23","doi-asserted-by":"publisher","unstructured":"Reiberger, T. et al. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble Guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis. Trials 24 (1). https:\/\/doi.org\/10.1186\/s13063-023-07291-3 (2023).","DOI":"10.1186\/s13063-023-07291-3"},{"key":"12381_CR24","doi-asserted-by":"publisher","unstructured":"Oldenburger, A. et al. Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices. Pharmacol. Res. Perspect. 9 (3). https:\/\/doi.org\/10.1002\/prp2.768 (2021).","DOI":"10.1002\/prp2.768"},{"issue":"5","key":"12381_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bbadis.2018.07.018","volume":"1865","author":"P K\u00f6nigshofer","year":"2019","unstructured":"K\u00f6nigshofer, P., Brusilovskaya, K., Schwabl, P. & Reiberger, T. Animal models of portal hypertension. Biochim. Biophys. Acta Mol. Basis Dis. 1865 (5), 1019\u20131030. https:\/\/doi.org\/10.1016\/j.bbadis.2018.07.018 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"12381_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1067\/msy.2001.110427","volume":"129","author":"MDM Arriero","year":"2001","unstructured":"Arriero, M. D. M. et al. Expression of inducible nitric oxide synthase in the liver of bile duct-ligated Wistar rats with modulation by lymphomononuclear cells. Surgery 129 (3), 255\u2013266. https:\/\/doi.org\/10.1067\/msy.2001.110427 (2001).","journal-title":"Surgery"},{"key":"12381_CR27","doi-asserted-by":"publisher","unstructured":"Tag, C. G. et al. Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J. Vis. Exp. (96). https:\/\/doi.org\/10.3791\/52438 (2015).","DOI":"10.3791\/52438"},{"issue":"5","key":"12381_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjp.0705318","volume":"139","author":"BJ Gibb","year":"2003","unstructured":"Gibb, B. J., Wykes, V. & Garthwaite, J. Properties of NO-activated guanylyl cyclases expressed in cells. Br. J. Pharmacol. 139 (5), 1032\u20131040. https:\/\/doi.org\/10.1038\/sj.bjp.0705318 (2003).","journal-title":"Br. J. Pharmacol."},{"key":"12381_CR29","doi-asserted-by":"crossref","unstructured":"Gupta, G., Azam, M., Yang, L. & Danziger, R. S. The B2 subunit inhibits stimulation of the A1\/B1 form of soluble guanylyl cyclase by nitric oxide potential relevance to regulation of blood pressure. 100 (1997). http:\/\/www.jci.org","DOI":"10.1172\/JCI119670"},{"key":"12381_CR30","doi-asserted-by":"publisher","unstructured":"El Ayadi, A., Jay, J. W. & Prasai, A. Current approaches targeting the wound healing phases to attenuate fibrosis and scarring. Int. J. Mol. Sci. 21 (3). https:\/\/doi.org\/10.3390\/ijms21031105 (2020).","DOI":"10.3390\/ijms21031105"},{"issue":"8","key":"12381_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.febslet.2006.02.080","volume":"580","author":"NA Davies","year":"2006","unstructured":"Davies, N. A. et al. Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study. FEBS Lett. 580 (8), 2123\u20132128. https:\/\/doi.org\/10.1016\/j.febslet.2006.02.080 (2006).","journal-title":"FEBS Lett."},{"issue":"1","key":"12381_CR32","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1038\/ncomms9482","volume":"6","author":"R Thoonen","year":"2015","unstructured":"Thoonen, R. et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nat. Commun. 6 (1), 8482. https:\/\/doi.org\/10.1038\/ncomms9482 (2015).","journal-title":"Nat. Commun."},{"issue":"3","key":"12381_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ueg2.12643","volume":"13","author":"BS Hofer","year":"2025","unstructured":"Hofer, B. S. et al. Inflammation remains a dynamic component of portal hypertension in regressive alcohol-related cirrhosis. United Eur. Gastroenterol. J. 13 (3), 317\u2013329. https:\/\/doi.org\/10.1002\/ueg2.12643 (2025).","journal-title":"United Eur. Gastroenterol. J."},{"key":"12381_CR34","doi-asserted-by":"publisher","unstructured":"Wu, S. et al. An update on animal models of liver fibrosis. Front. Med. (Lausanne). 10 https:\/\/doi.org\/10.3389\/fmed.2023.1160053 (2023).","DOI":"10.3389\/fmed.2023.1160053"},{"key":"12381_CR35","doi-asserted-by":"publisher","unstructured":"du Sert, N. P. et al. Reporting animal research: explanation and elaboration for the arrive guidelines 2.0. PLoS Biol. 18 (7). https:\/\/doi.org\/10.1371\/journal.pbio.3000411 (2020).","DOI":"10.1371\/journal.pbio.3000411"},{"key":"12381_CR36","doi-asserted-by":"publisher","unstructured":"K\u00f6nigshofer, P. et al. Invasive hemodynamic characterization of the portal-hypertensive syndrome in cirrhotic rats. J. Vis. Exp. 2018 (138). https:\/\/doi.org\/10.3791\/57261 (2018).","DOI":"10.3791\/57261"},{"issue":"4","key":"12381_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u2206\u2206CT method. Methods 25 (4), 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"issue":"5\u20136","key":"12381_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jchromb.2008.12.063","volume":"877","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. et al. Development and validation of an LC\u2013MS\/MS method for quantification of Cyclic Guanosine 3\u2032,5\u2032-monophosphate (cGMP) in clinical applications: a comparison with a EIA method. J. Chromatogr. B. 877 (5\u20136), 513\u2013520. https:\/\/doi.org\/10.1016\/j.jchromb.2008.12.063 (2009).","journal-title":"J. Chromatogr. B"},{"issue":"3","key":"12381_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods. 17 (3), 261\u2013272. https:\/\/doi.org\/10.1038\/s41592-019-0686-2 (2020).","journal-title":"Nat. Methods"},{"issue":"60","key":"12381_CR40","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"M Waskom","year":"2021","unstructured":"Waskom, M. Seaborn: statistical data visualization. J. Open. Sour. Softw. 6 (60), 3021. https:\/\/doi.org\/10.21105\/joss.03021 (2021).","journal-title":"J. Open. Sour. Softw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12381-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:11:44Z","timestamp":1753427504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12381-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12381"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12381-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TR received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept\/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking honoraria from Abbvie, Gilead, Intercept\/Advanz Pharma, Roche, MSD, W. L. Gore & Associates; consulting\/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept\/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead and Roche. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda and UltraGenyx; honoraria for consulting from AbbVie, Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Hightide, Intercept, Jannsen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire; speaker fees from Albireo, Bristol-Myers Squibb, Falk, Gilead, Intercept, MSD and Madrigal; and travel support from AbbVie, Falk, Gilead and Intercept. PSc received consulting fees from PharmaIN and payment for manuscript writing from the Falk Foundation. PSu, IT and SK are employed by Boehringer Ingelheim Pharma GmbH & Co.KG. BS received travel support from AbbVie and Gilead. BSH received travel support from Falk and Ipsen. TS, KBr, PK, OP, VT, KBo, HH, KZ, CL and KR declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27051"}}